• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MediciNova, Inc. - Common Stock (NQ:MNOV)

    1.880 -0.700 (-27.13%)
    Streaming Delayed Price Updated: 11:15 AM EDT, Sep 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 904,380
    Open 2.400
    Bid (Size) 1.870 (100)
    Ask (Size) 1.890 (200)
    Prev. Close 2.580
    Today's Range 1.860 - 2.450
    52wk Range 1.168 - 3.900
    Shares Outstanding 49,046,246
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
    MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat 
    From MediciNova, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +41.4%
    +41.4%
    1 Month
    +31.0%
    +31.0%
    3 Month
    +43.5%
    +43.5%
    6 Month
    +38.2%
    +38.2%
    1 Year
    +50.4%
    +50.4%

    More News

    Read More
    News headline image
    MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
    From MediciNova, Inc.
    Via GlobeNewswire
    Unusual volume stocks in Tuesday's session ↗
    Via Chartmill
    Unusual volume stocks in Monday's session ↗
    Via Chartmill
    Unusual volume stocks in Friday's session ↗
    Via Chartmill
    News headline image
    MediciNova to Participate in Two Investor Conferences in September
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova CEO Provides Shareholder Update
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova to Participate at the 38th Annual ROTH Conference
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    2026 New Year’s Greetings from the CEO
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    Message from the CEO to MediciNova Shareholders
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    Unusual volume stocks in Monday's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill

    Frequently Asked Questions

    Is MediciNova, Inc. - Common Stock publicly traded?
    Yes, MediciNova, Inc. - Common Stock is publicly traded.
    What exchange does MediciNova, Inc. - Common Stock trade on?
    MediciNova, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MediciNova, Inc. - Common Stock?
    The ticker symbol for MediciNova, Inc. - Common Stock is MNOV on the Nasdaq Stock Market
    What is the current price of MediciNova, Inc. - Common Stock?
    The current price of MediciNova, Inc. - Common Stock is 1.880
    When was MediciNova, Inc. - Common Stock last traded?
    The last trade of MediciNova, Inc. - Common Stock was at 09/28/26 11:15 AM ET
    What is the market capitalization of MediciNova, Inc. - Common Stock?
    The market capitalization of MediciNova, Inc. - Common Stock is 92.21M
    How many shares of MediciNova, Inc. - Common Stock are outstanding?
    MediciNova, Inc. - Common Stock has 92M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.